10.6084/M9.FIGSHARE.15048920.V1
Xiaohua Sun
Xiaohua
Sun
Jizheng Zhang
Jizheng
Zhang
Yi Li
Yi
Li
Wanlu Ren
Wanlu
Ren
Lijun Wang
Lijun
Wang
Etomidate ameliorated advanced glycation end-products (AGEs)-induced reduction of extracellular matrix genes expression in chondrocytes
<p>Osteoarthritis (OA) is a rheumatic disease common in the elderly. AGEs are the end products of glycation reactions and play an important role in the development of OA. Etomidate is a general anesthesia-inducing agent recently reported to exert significant anti-inflammatory effects. The present study aims to explore the protective effect of Etomidate against advanced glycation end-products (AGEs)-induced reduction of extracellular matrix gene expression in chondrocytes. In the present study, we found that AGEs significantly reduced the expression of Collagen II (<i>COL2A1</i>) and Aggrecan (<i>ACAN</i>) at the gene level. Furthermore, AGEs inhibited the expression of SRY-related high mobility group-box gene 9 (SOX-9), promoting the expression of COL2A1 and ACAN. <i>COL2A1, ACAN</i>, and <i>SOX-9</i> in chondrocytes were significantly elevated by treatment with Etomidate alone. Consistently, Etomidate ameliorated AGEs-induced downregulation of <i>COL2A1, ACAN</i>, and SOX-9 in a dose-dependent manner. Importantly, we found that knockdown of SOX-9 eliminated the beneficial effects of Etomidate against AGEs-induced decrease in <i>COL2A1 and ACAN genes</i>. Based on these findings, we demonstrated that Etomidate could ameliorate AGEs-induced reduction of extracellular matrix gene expression in chondrocytes by upregulating SOX-9.</p>
Biochemistry
Medicine
Microbiology
Cell Biology
Genetics
Molecular Biology
Physiology
Ecology
Immunology
Biological Sciences not elsewhere classified
Developmental Biology
Marine Biology
Cancer
Virology
Taylor & Francis
2021
2021-07-25
2024-02-20
Figure
90274 Bytes
10.6084/m9.figshare.15048920
10.1080/21655979.2021.1951926
CC BY 4.0